Were Karthik Kuppusamy’s Quest Diagnostics (DGX) purchases related to a company stock purchase plan?

The reported direct share amount of 13,557 includes exempt purchases made under Quest Diagnostics’ stock purchase plan since his last Form 4. Footnote disclosure explains that these exempt plan purchases are aggregated into the current reported holdings figure.

Quest Diagnostics executive acquires 37 shares

Q: What insider transaction did Quest Diagnostics (DGX) report for Karthik Kuppusamy?

Quest Diagnostics reported that SVP Clinical Solutions Karthik Kuppusamy acquired 37 shares of common stock at $206.807 per share. The shares were obtained through a broker-administered dividend reinvestment plan and qualify for deferred reporting under Rule 16a-6 but were reported early.

Q: What is the significance of Rule 16a-6 in Karthik Kuppusamy’s Quest Diagnostics (DGX) transaction?

The acquired 37 shares were eligible for deferred reporting on Form 5 under Rule 16a-6, which covers certain small acquisitions. Karthik Kuppusamy chose instead to report this dividend reinvestment transaction early on Form 4, providing more timely public disclosure.

Q: How were Karthik Kuppusamy’s Quest Diagnostics (DGX) 401(k) shares determined?

The 1,691 Quest Diagnostics shares attributed to Karthik Kuppusamy’s 401(k) were acquired periodically by the plan trustee. The reported amount equals his Company stock fund balance, including some money market instruments, divided by the stock’s market price as of the plan’s current valuation date.

Accepted by SEC EDGAR 07/27/2026 - 04:35 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Quest Diagnostics executive Karthik Kuppusamy, SVP Clinical Solutions, reported a small acquisition of 37 shares of common stock at $206.807 per share under a broker-administered dividend reinvestment plan, eligible for deferred Form 5 reporting under Rule 16a-6 but reported early. His direct holdings total 13,557 shares, with additional indirect holdings of 358 shares in a trust and 1,691 shares in the company’s 401(k) Profit Sharing Plan.

Insider Trade Summary

Small Acquisition: 37 shares

Small Acquisition 1 txn

Insider KUPPUSAMY KARTHIK

Role SVP, Clinical Solutions

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock ^{F1, F2}	37	$206.807	$8K
Holding	Common Stock	--	--	--
Holding	Common Stock ^F3	--	--	--

Holdings After Transaction: Common Stock — 13,557 shares (Direct); Common Stock — 358 shares (Indirect, By Trust); Common Stock — 1,691 shares (Indirect, 401(k))

Footnotes (3)

F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
F2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
F3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Key Figures

Shares acquired: 37 shares Acquisition price: $206.807 per share Direct holdings after transaction: 13,557 shares +2 more

5 metrics

Shares acquired 37 shares Common Stock acquired on 2026-07-22 under dividend reinvestment plan

Acquisition price $206.807 per share Price for the 37-share dividend reinvestment acquisition

Direct holdings after transaction 13,557 shares Direct Quest Diagnostics common stock held by Karthik Kuppusamy after the acquisition

Trust holdings 358 shares Indirect ownership classified as "By Trust"

401(k) plan holdings 1,691 shares Indirect ownership through the Company’s tax qualified Profit Sharing (401(k)) Plan

Key Terms

dividend reinvestment plan, Rule 16a-6, Profit Sharing (401(k)) Plan

3 terms

dividend reinvestment plan financial

"shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) report for Karthik Kuppusamy?

Quest Diagnostics reported that SVP Clinical Solutions Karthik Kuppusamy acquired 37 shares of common stock at $206.807 per share. The shares were obtained through a broker-administered dividend reinvestment plan and qualify for deferred reporting under Rule 16a-6 but were reported early.

How many Quest Diagnostics (DGX) shares does Karthik Kuppusamy now hold directly and indirectly?

After the reported acquisition, Karthik Kuppusamy directly holds 13,557 Quest Diagnostics shares. He also has indirect holdings of 358 shares held by a trust and 1,691 shares held through the company’s tax-qualified Profit Sharing (401(k)) Plan as reported from plan data.

What is the significance of Rule 16a-6 in Karthik Kuppusamy’s Quest Diagnostics (DGX) transaction?

The acquired 37 shares were eligible for deferred reporting on Form 5 under Rule 16a-6, which covers certain small acquisitions. Karthik Kuppusamy chose instead to report this dividend reinvestment transaction early on Form 4, providing more timely public disclosure.

How were Karthik Kuppusamy’s Quest Diagnostics (DGX) 401(k) shares determined?

The 1,691 Quest Diagnostics shares attributed to Karthik Kuppusamy’s 401(k) were acquired periodically by the plan trustee. The reported amount equals his Company stock fund balance, including some money market instruments, divided by the stock’s market price as of the plan’s current valuation date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUPPUSAMY KARTHIK

(Last)

(First)

(Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS

NEW JERSEY

07094

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Clinical Solutions

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/22/2026		L	V	37⁽¹⁾	A	$206.807	13,557⁽²⁾	D
Common Stock								358	I	By Trust
Common Stock								1,691⁽³⁾	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Karthik Kuppusamy	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR